Rheumatoid Arthritis

The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.
[[thumbnail_alt_text]]
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs. 
[[thumbnail_alt_text]]
Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).
[[thumbnail_alt_text]]
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.
[[thumbnail_alt_text]]
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) agreed on a positive opinion for AbbVie’s upadacitinib (RINVOQ), according to the company.
[[thumbnail_alt_text]]
Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). 
[[thumbnail_alt_text]]
Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
[[thumbnail_alt_text]]
Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.
[[thumbnail_alt_text]]
Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.
[[thumbnail_alt_text]]
A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.
[[thumbnail_alt_text]]
The higher dose is only approved for patients with ulcerative colitis, and not for RA.
[[thumbnail_alt_text]]
The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.